Aldeyra Therapeutics Inc’s filing revealed that its Chief Development Officer Machatha Stephen unloaded Company’s shares for reported $75975.0 on Aug 12 ’24. In the deal valued at $4.74 per share,16,041 shares were sold. As a result of this transaction, Machatha Stephen now holds 236,771 shares worth roughly $1.54 million.
Then, Greenberg Bruce sold 10,834 shares, generating $51,313 in total proceeds. Upon selling the shares at $4.74, the insider now owns 126,382 shares.
Before that, Greenberg Bruce bought 10,834 shares. Aldeyra Therapeutics Inc shares valued at $55,253 were divested by the Officer at a price of $5.10 per share.
Oppenheimer upgraded its Aldeyra Therapeutics Inc [ALDX] rating to an Outperform from a a Perform in a research note published recently. H.C. Wainwright started covering the stock on February 08, 2021. It rated ALDX as “a Buy”.
Price Performance Review of ALDX
On Tuesday, Aldeyra Therapeutics Inc [NASDAQ:ALDX] saw its stock unchanged to $6.50. Over the last five days, the stock has lost -1.66%. Aldeyra Therapeutics Inc shares have risen nearly 30.26% since the year began. Nevertheless, the stocks have risen 83.62% over the past one year. While a 52-week high of $6.92 was reached on 02/18/25, a 52-week low of $2.71 was recorded on 01/13/25. SMA at 50 days reached $5.40, while 200 days put it at $4.85.
Levels Of Support And Resistance For ALDX Stock
The 24-hour chart illustrates a support level at 6.34, which if violated will result in even more drops to 6.17. On the upside, there is a resistance level at 6.63. A further resistance level may holdings at 6.75. The Relative Strength Index (RSI) on the 14-day chart is 66.99, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 25.93%. Stochastics %K at 79.40% indicates the stock is a holding.
The most recent change occurred on December 16, 2020 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
